PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ImmunityBio, Inc. (IBRX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS45256X1037
CUSIP45256X103
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$5.62B
EPS-$1.15
Revenue (TTM)$622.00K
Gross Profit (TTM)$240.00K
EBITDA (TTM)-$342.85M
Year Range$1.25 - $10.53
Target Price$7.50
Short %39.03%
Short Ratio12.10

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


ImmunityBio, Inc.

Popular comparisons: IBRX vs. BLUE, IBRX vs. ACIC, IBRX vs. QQQ, IBRX vs. FNGU, IBRX vs. NVDA, IBRX vs. VITL

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in ImmunityBio, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%150.00%December2024FebruaryMarchAprilMay
-75.75%
150.65%
IBRX (ImmunityBio, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

ImmunityBio, Inc. had a return of 67.33% year-to-date (YTD) and 160.87% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date67.33%10.00%
1 month64.38%2.41%
6 months131.40%16.70%
1 year160.87%26.85%
5 years (annualized)50.04%12.81%
10 years (annualized)N/A10.84%

Monthly Returns

The table below presents the monthly returns of IBRX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-33.07%40.77%13.53%48.79%67.33%
2023-25.05%-35.79%-25.41%53.85%-1.79%1.09%-20.86%-26.82%4.97%85.80%17.20%36.41%-0.99%
2022-4.28%17.53%-17.98%-35.29%3.58%-1.06%4.57%2.83%24.25%10.66%0.18%-7.99%-16.61%
202141.60%72.24%-26.98%-25.23%-1.13%-18.63%-23.25%3.83%-14.41%-19.61%-0.51%-21.95%-54.39%
202066.75%-23.42%-40.50%35.42%72.82%82.20%-8.96%-34.70%-5.00%8.29%27.56%39.14%251.72%
2019-6.90%4.63%39.82%-29.11%-8.04%-0.97%35.29%-5.80%-6.15%-13.93%63.81%120.35%226.72%
2018-1.56%0.45%-12.39%0.26%-6.15%-16.39%14.38%-3.14%9.14%-41.08%-21.56%-32.16%-74.16%
2017-6.29%-11.75%-24.95%-11.27%16.51%106.81%-14.89%-3.56%-12.04%-15.69%6.06%-8.37%-21.50%
2016-40.57%-33.20%19.48%0.85%-8.08%-18.37%9.81%18.45%-3.83%-23.01%9.18%-12.54%-66.99%
2015-11.66%-44.05%-33.06%3.84%37.06%6.25%-49.97%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current risk-adjusted rank of IBRX is 90, placing it in the top 10% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of IBRX is 9090
IBRX (ImmunityBio, Inc.)
The Sharpe Ratio Rank of IBRX is 9292Sharpe Ratio Rank
The Sortino Ratio Rank of IBRX is 9090Sortino Ratio Rank
The Omega Ratio Rank of IBRX is 8686Omega Ratio Rank
The Calmar Ratio Rank of IBRX is 9595Calmar Ratio Rank
The Martin Ratio Rank of IBRX is 9090Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for ImmunityBio, Inc. (IBRX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


IBRX
Sharpe ratio
The chart of Sharpe ratio for IBRX, currently valued at 2.04, compared to the broader market-2.00-1.000.001.002.003.004.002.04
Sortino ratio
The chart of Sortino ratio for IBRX, currently valued at 2.91, compared to the broader market-4.00-2.000.002.004.006.002.91
Omega ratio
The chart of Omega ratio for IBRX, currently valued at 1.34, compared to the broader market0.501.001.502.001.34
Calmar ratio
The chart of Calmar ratio for IBRX, currently valued at 2.77, compared to the broader market0.002.004.006.002.77
Martin ratio
The chart of Martin ratio for IBRX, currently valued at 9.25, compared to the broader market-10.000.0010.0020.0030.009.25
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.35, compared to the broader market-2.00-1.000.001.002.003.004.002.35
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.33, compared to the broader market-4.00-2.000.002.004.006.003.33
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.41, compared to the broader market0.501.001.502.001.41
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.90, compared to the broader market0.002.004.006.001.90
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 9.02, compared to the broader market-10.000.0010.0020.0030.009.02

Sharpe Ratio

The current ImmunityBio, Inc. Sharpe ratio is 2.04. This value is calculated based on the past 12 months of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of ImmunityBio, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.002.503.00December2024FebruaryMarchAprilMay
2.04
2.35
IBRX (ImmunityBio, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


ImmunityBio, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%December2024FebruaryMarchAprilMay
-80.12%
-0.15%
IBRX (ImmunityBio, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the ImmunityBio, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ImmunityBio, Inc. was 97.14%, occurring on Jun 10, 2019. Recovery took 427 trading sessions.

The current ImmunityBio, Inc. drawdown is 80.12%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-97.14%Jul 30, 2015972Jun 10, 2019427Feb 18, 20211399
-97.03%Feb 23, 2021670Oct 19, 2023

Volatility

Volatility Chart

The current ImmunityBio, Inc. volatility is 53.33%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%December2024FebruaryMarchAprilMay
53.33%
3.35%
IBRX (ImmunityBio, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of ImmunityBio, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items